Clinical experience of afatinib application In non-cell lung cancer of lung. Ii line of therapy
Authors: L.M. Kogoniya, E.V. Markarova, G.A. Stashuk, V.E. Shikina
The purpose of this report is to analyze your own clinical data on the usefulness of apathinib in the second line of therapy for pulmonary adenocarcinoma. On the basis of MONIKI medical institutions, material was accumulated for 12 patients with lung adenocarcinoma who received the second line of therapy with Afatinib.